Can-Fite's Namodenoson Shows Durable Survival in Pancreatic Cancer Trial
Event summary
- Can-Fite's Phase 2a study of Namodenoson in advanced pancreatic cancer accepted for ESMO Congress 2026 poster presentation.
- Study demonstrated durable disease stabilization and survival benefits in predominantly third-line patients.
- One patient receiving Namodenoson as second-line therapy remains alive beyond 18 months.
- Company planning Phase 2b combination study with chemotherapy based on encouraging results.
The big picture
Can-Fite's positive Phase 2a data for Namodenoson in pancreatic cancer comes at a time when the oncology field is increasingly focused on targeted therapies for aggressive malignancies. The acceptance by ESMO underscores growing scientific interest in A3 adenosine receptor agonists as potential game-changers in cancer treatment. With limited options for advanced pancreatic cancer patients, successful development of Namodenoson could position Can-Fite as a key player in this high-unmet-need market.
What we're watching
- Clinical Validation
- Whether ESMO presentation will enhance Namodenoson's scientific credibility and attract potential partners.
- Development Strategy
- The pace at which Can-Fite advances the Phase 2b combination study and secures regulatory support.
- Market Differentiation
- How Namodenoson's unique mechanism of action positions it against existing pancreatic cancer therapies.
Related topics